OBJECTIVES: To assess the effect of cardiopulmonary bypass on allograft function and recipient survival in double-lung transplantation. METHODS: Retrospective review of 94 double-lung transplantations. RESULTS: Cardiopulmonary bypass was used in 37 patients (CPB); 57 transplantations were accomplished without bypass (no-CPB). Bypass was routinely used for patients with pulmonary hypertension (n = 27) and for two recipients undergoing en bloc transplantation. Cardiopulmonary bypass was required in eight (12.3%) of the remaining 65 patients. Mean ischemic time was longer in the CPB group (346 vs 315 minutes, p = 0.04). The CPB group required more perioperative blood (11.4 vs 6.0 units, p = 0.01). Allograft function, assessed by the arterial/alveolar oxygen tension ratio, was better in the no-CPB group at 12 and 24 hours after operation (0.54 vs 0.39 at 12 hours, p = 0.002; and 0.63 vs 0.38 at 24 hours, p = 0.001). The CPB group had more severe pulmonary infiltrates at both 1 and 24 hours (p = 0.005). Diffuse alveolar damage was more common in the CPB group (69% vs 35%, p = 0.002). Median duration of intubation was longer in the CPB group (10 days) than in the no-CPB group (2 days, p = 0.002). The 30-day mortality rate (13.5% vs 7.0% in the CPB and no-CPB groups) and 1-year survival (65% vs 67%, CPB and no-CPB) were not significantly different. CONCLUSIONS: In the absence of pulmonary hypertension, cardiopulmonary bypass is only occasionally necessary in double-lung transplantation. Bypass is associated with substantial early allograft dysfunction after transplantation.
OBJECTIVES: To assess the effect of cardiopulmonary bypass on allograft function and recipient survival in double-lung transplantation. METHODS: Retrospective review of 94 double-lung transplantations. RESULTS: Cardiopulmonary bypass was used in 37 patients (CPB); 57 transplantations were accomplished without bypass (no-CPB). Bypass was routinely used for patients with pulmonary hypertension (n = 27) and for two recipients undergoing en bloc transplantation. Cardiopulmonary bypass was required in eight (12.3%) of the remaining 65 patients. Mean ischemic time was longer in the CPB group (346 vs 315 minutes, p = 0.04). The CPB group required more perioperative blood (11.4 vs 6.0 units, p = 0.01). Allograft function, assessed by the arterial/alveolar oxygen tension ratio, was better in the no-CPB group at 12 and 24 hours after operation (0.54 vs 0.39 at 12 hours, p = 0.002; and 0.63 vs 0.38 at 24 hours, p = 0.001). The CPB group had more severe pulmonary infiltrates at both 1 and 24 hours (p = 0.005). Diffuse alveolar damage was more common in the CPB group (69% vs 35%, p = 0.002). Median duration of intubation was longer in the CPB group (10 days) than in the no-CPB group (2 days, p = 0.002). The 30-day mortality rate (13.5% vs 7.0% in the CPB and no-CPB groups) and 1-year survival (65% vs 67%, CPB and no-CPB) were not significantly different. CONCLUSIONS: In the absence of pulmonary hypertension, cardiopulmonary bypass is only occasionally necessary in double-lung transplantation. Bypass is associated with substantial early allograft dysfunction after transplantation.
Authors: Christopher A Heid; Mitri K Khoury; Kayla Maaraoui; Charles Liu; Matthias Peltz; Michael A Wait; W Steves Ring; Lynn C Huffman Journal: J Surg Res Date: 2020-06-26 Impact factor: 2.192
Authors: Dimitrios E Magouliotis; Vasiliki S Tasiopoulou; Alexis A Svokos; Konstantina A Svokos; Dimitris Zacharoulis Journal: Gen Thorac Cardiovasc Surg Date: 2017-09-16
Authors: Satish Chandrashekaran; Cesar A Keller; Walter K Kremers; Steve G Peters; Matthew A Hathcock; Cassie C Kennedy Journal: J Heart Lung Transplant Date: 2014-11-17 Impact factor: 10.247
Authors: Rupal J Shah; Joshua M Diamond; Edward Cantu; James C Lee; David J Lederer; Vibha N Lama; Jonathan Orens; Ann Weinacker; David S Wilkes; Sangeeta Bhorade; Keith M Wille; Lorraine B Ware; Scott M Palmer; Maria Crespo; A Russell Localio; Ejigayehu Demissie; Steven M Kawut; Scarlett L Bellamy; Jason D Christie Journal: Chest Date: 2013-08 Impact factor: 9.410
Authors: David J Lederer; Jessie S Wilt; Frank D'Ovidio; Matthew D Bacchetta; Lori Shah; Shankari Ravichandran; Jenny Lenoir; Brenda Klein; Joshua R Sonett; Selim M Arcasoy Journal: Am J Respir Crit Care Med Date: 2009-07-16 Impact factor: 21.405
Authors: Joshua M Diamond; James C Lee; Steven M Kawut; Rupal J Shah; A Russell Localio; Scarlett L Bellamy; David J Lederer; Edward Cantu; Benjamin A Kohl; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Joshua Sonett; Keith Wille; Jonathan Orens; Ashish S Shah; Ann Weinacker; Selim Arcasoy; Pali D Shah; David S Wilkes; Lorraine B Ware; Scott M Palmer; Jason D Christie Journal: Am J Respir Crit Care Med Date: 2013-01-10 Impact factor: 21.405
Authors: Joshua M Diamond; Mary K Porteous; Edward Cantu; Nuala J Meyer; Rupal J Shah; David J Lederer; Steven M Kawut; James Lee; Scarlett L Bellamy; Scott M Palmer; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Keith Wille; Jonathan Orens; Pali D Shah; Ann Weinacker; David Weill; Selim Arcasoy; David S Wilkes; Lorraine B Ware; Jason D Christie Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240